Adaptive Biotechnologies (ADPT) Current Assets (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Current Assets data on file, last reported at $291.8 million in Q1 2026.

• Quarterly Current Assets rose 13.77% year-over-year to $291.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $291.8 million (up 13.77% YoY) and the FY2025 annual result came in at $300.2 million, up 5.79% from the prior year.
• Current Assets slipped to $291.8 million in Q1 2026 per ADPT's latest filing, from $300.2 million in the prior quarter.
• The five-year high for Current Assets was $564.4 million in Q3 2022, with the low at $256.5 million in Q1 2025.
• Average Current Assets over 5 years is $383.4 million, with a median of $374.0 million recorded in 2024.
• The widest YoY moves for Current Assets: up 39.58% in 2022, down 45.21% in 2022.
• Adaptive Biotechnologies' Current Assets stood at $562.1 million in 2022, then decreased by 27.03% to $410.2 million in 2023, then tumbled by 30.82% to $283.8 million in 2024, then rose by 5.79% to $300.2 million in 2025, then decreased by 2.79% to $291.8 million in 2026.
• Business Quant data shows ADPT's Current Assets at $291.8 million in Q1 2026, $300.2 million in Q4 2025, and $281.4 million in Q3 2025.